BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 55 resultados LastUpdate Última actualización 18/01/2019 [17:53:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


POLYTHERAPY MODULATING CATHELICIDIN GENE EXPRTESSION MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER CONDITIONS

NºPublicación: US2019015361A1 17/01/2019

Solicitante:
MAXWELL BIOSCIENCES INC [US]

Resumen de: US2019015361A1

A polytherapy of orally available compounds is disclosed that synergistically modulates and induces the expression of the cathelicidin gene (CAMP), which encodes the host defense peptide LL-37. By providing a number of different CAMP-inducing compounds together at the same time, stronger gene induction is achieved than with just one or two compounds, because the mechanism of induction broadens. Induction also may vary in different parts of the body depending on which compounds are used, and at what levels. We show for the first time that the polytherapy can induce cathelicidin expression in the brain, which may help to treat or prevent Alzheimer's Disease. Systemic cathelicidin gene induction may help treat numerous other conditions including Type 2 Diabetes/Metabolic Syndrome, or chronic bacterial, viral, or fungal infections associated with increased cancer risk or neurodegeneration. By increasing cellular autophagy and macroautophagy and supporting mitochondrial biogenesis and homeostasis, CAMP gene upregulation may reduce the effects of cellular aging and increase longevity.



traducir


 

A DEVICE FOR NON-INVASIVE TREATMENT OF NEURODEGENERATIVE DISEASES

NºPublicación: WO2019012556A1 17/01/2019

Solicitante:
INDIAN INSTITUTE OF TECH GUWAHATI [IN]

Resumen de: WO2019012556A1

The present invention provides a device for treating neurodegenerative diseases including but not limiting to Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis using electric field. More specifically, the invention provides a device which generates focused AC/DC electric field specifically targeting dense insoluble deposits of amyloid-beta (A) peptide outside and around neurons in the brain of a patient. This mode of action serves as a non-invasive therapeutic tool for disruption of the inherent -sheet conformation known to be the reason for fibril formation.



traducir


 

BIOMARKER FOR COGNITIVE IMPAIRMENT DISORDERS AND DETECTION METHOD FOR COGNITIVE IMPAIRMENT DISORDERS USING SAID BIOMARKER

NºPublicación: WO2019012671A1 17/01/2019

Solicitante:
MCBI INC [JP]
UCHIDA KAZUHIKO [JP]

Resumen de: WO2019012671A1

Provided are: a method for improving the detection accuracy of cognitive impairment disorders by, in addition to assessment by a medical practitioner using past diagnosis criteria for cognitive impairment disorders such as Alzheimer's disease, referring to the measurement results for one or more types of biomarkers for detecting cognitive impairment disorders in a biological sample from a subject; and a method for accurately detecting cognitive impairment disorders even with only the measurement results for one or more types of biomarkers for detecting cognitive impairment disorders in a biological sample from a subject. The present invention measures, in a biological sample from a subject, one or more types of biomarkers for detecting cognitive impairment disorders selected from the biomarkers in (a) to (g). (a) A biomarker for detecting cognitive impairment disorders and comprising a peptide which includes the amino acid sequence represented by SEQ ID NO: 1; (b) a biomarker for detecting cognitive impairment disorders and comprising a peptide which includes the amino acid sequence represented by SEQ ID NO: 2; (c) a biomarker for detecting cognitive impairment disorders and comprising a peptide which includes the amino acid sequence represented by SEQ ID NO: 3; (d) a biomarker for detecting cognitive impairment disorders and comprising a peptide which includes the amino acid sequence represented by SEQ ID NO: 4; (e) a biomarker for detecting cognitive impairment disorder



traducir


 

BIOMARKER FOR COGNITIVE IMPAIRMENT DISORDERS AND DETECTION METHOD FOR COGNITIVE IMPAIRMENT DISORDERS USING SAID BIOMARKER

NºPublicación: WO2019012667A1 17/01/2019

Solicitante:
MCBI INC [JP]
UCHIDA KAZUHIKO [JP]

Resumen de: WO2019012667A1

Provided are: a method for detecting cognitive impairment disorders including mild cognitive impairment and Alzheimer's disease using a protein that is present in different amounts in subjects with normal cognitive function and patients with cognitive impairment disorders, and a peptide of said protein; and a biomarker comprising said protein and said peptide and for detecting cognitive impairment disorders including mild cognitive impairment and Alzheimer's disease. The present invention is: a biomarker for diagnosing cognitive impairment disorders and comprising the peptide THRB, which is a prothrombin precursor protein in SEQ ID NO: 1 or a peptide thereof and comprises the amino acid sequence represented by SEQ ID NO: 2; a diagnosis method for cognitive impairment disorders using the biomarker; an antigen peptide represented by SEQ ID NO: 3 for creating a THRB peptide-specific antibody to be used in the diagnosis method; and a cognitive impairment disorder diagnosis kit containing the THRB peptide-specific antibody.



traducir


 

DETECTION OF NEURODEGENERATIVE DISEASES

NºPublicación: EP3426667A2 16/01/2019

Solicitante:
AMONETA DIAGNOSTICS SAS [FR]
JPT PEPTIDE TECH GMBH [DE]
CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENT [FR]
UNIV DE STRASBOURG [FR]

Resumen de: WO2017153922A2

The present invention relates to novel compounds, their uses as biomarker, and/or methods including a non-invasive in vitro method using this biomarker, for diagnosing or monitoring the development or the progression of Alzheimer's disease (AD) or a disease or disorder associated with β-amyloid peptide (Aβ) deposition or tau hyperphosphorylation or a disease or disorder characterized by a proteinopathy implicating abnormalities in protein kinase C (PKC).



traducir


 

ANTIBODIES RECOGNIZING TAU

NºPublicación: CN109219615A 15/01/2019

Solicitante:
\u666E\u7F57\u585E\u7EB3\u751F\u7269\u79D1\u5B66\u6709\u9650\u516C\u53F8

Resumen de: WO2017191560A1

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.



traducir


 

SPECIALIZED EXCITATORY SYNAPTIC PROTEIN BIOMARKERS OF PLASMA NEURONAL EXOSOMES FOR PREDICTION AND STAGING OF ALZHEIMER'S DISEASE

NºPublicación: WO2019009985A1 10/01/2019

Solicitante:
GOETZL EDWARD J [US]

Resumen de: WO2019009985A1

Combining presynaptic proteins, neuronal pentraxin 2 (NPTX2) and neurexin 2α (NRXN2a), with respective postsynaptic functional partners GluA4-containing glutamate receptor (AMPA4) and neuroligin 1 (NLGN1), and enhancing excitatory synaptic activities in areas of the hippocampus and cerebral cortex. As early damage of such excitatory circuits in Alzheimer' s disease (AD) correlates with cognitive losses, plasma neuron- derived exosome (NDE) levels of these two pairs of synaptic proteins are quantified and serve as biomarkers. NDE contents of all four proteins decrease significantly in AD dementia and diminished levels of AMPA4 and NLGN1 correlate with the extent of cognitive losses. Prior to the onset of dementia, NDE levels of all but NPTX2 are significantly lower than those of matched control subjects and levels of all decline significantly with the development of dementia. Reductions in NDE levels of these excitatory synaptic proteins are indicators of cognitive losses and reflect progression of severity of AD.



traducir


 

SPECIALIZED EXCITATORY SYNAPTIC PROTEIN BIOMARKERS OF PLASMA NEURONAL EXOSOMES FOR PREDICTION AND STAGING OF ALZHEIMER'S DISEASE

NºPublicación: US2019011460A1 10/01/2019

Solicitante:
GOETZL EDWARD J [US]

Resumen de: US2019011460A1

Combining presynaptic proteins, neuronal pentraxin 2 (NPTX2) and neurexin 2α (NRXN2α), with respective postsynaptic functional partners GluA4-containing glutamate receptor (AMPA4) and neuroligin 1 (NLGN1), and enhancing excitatory synaptic activities in areas of the hippocampus and cerebral cortex. As early damage of such excitatory circuits in Alzheimer's disease (AD) correlates with cognitive losses, plasma neuron-derived exosome (NDE) levels of these two pairs of synaptic proteins are quantified and serve as biomarkers. NDE contents of all four proteins decrease significantly in AD dementia and diminished levels of AMPA4 and NLGN1 correlate with the extent of cognitive losses. Prior to the onset of dementia, NDE levels of all but NPTX2 are significantly lower than those of matched control subjects and levels of all decline significantly with the development of dementia. Reductions in NDE levels of these excitatory synaptic proteins are indicators of cognitive losses and reflect progression of severity of AD.



traducir


 

HUMAN ALZHEIMER'S DISEASE AND TRAUMATIC BRAIN INJURY ASSOCIATED TAU VARIANTS AS BIOMARKERS AND METHODS OF USE THEREOF

NºPublicación: US2019010504A1 10/01/2019

Solicitante:
UNIV ARIZONA STATE [US]

Resumen de: US2019010504A1

The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI) and/or susceptibility to neurodegenerative disease in a subject.



traducir


 

An Apparatus and Method for Cerebral Microdialysis to Treat Neurological Disease, Including Alzheimer's, Parkinson's or Multiple Sclerosis

NºPublicación: US2019009014A1 10/01/2019

Solicitante:
COGNOS THERAPEUTICS INC [US]

Resumen de: US2019009014A1

An apparatus for performing cerebral micro-dialysis to treat neurological disease of a patient's brain includes a catheter for implantation in or near the patient's brain, an implantable pump communicated with the catheter to transport cerebrospinal fluid (CSF) from the patient, which CSF contains diseased cells or biomolecules associated with the neurological disease, and an implantable separation device communicated with the pump wherein the diseased cells or biomolecules are removed, where the separation apparatus includes a dialysis membrane impregnated with an antibody, a reversible electrostatic filter, and/or a magnetic field effect fractionation chamber wherein a magnetically-tagged antibody scavenges and aids in the removal of circulating diseased cells or biomolecules from the CSF.



traducir


 

PARTICLE SIZE PURIFICATION METHOD AND DEVICES

NºPublicación: US2019011342A1 10/01/2019

Solicitante:
UNIV NOTRE DAME DU LAC [US]

Resumen de: US2019011342A1

A panicle separation multi-membrane matrix device and method are provided. The particles isolated may comprise noun-scale particles, such extracellular membrane vesicles, having a size of about 50 to about 150 nm. The vesicles are released by many different cell types, and may be efficiently isolated at high yield and purity according to the present methods from various body fluids (e.g., blood, saliva, breast milk, serum, plasma, ascites fluid, etc.). Such isolated exosome preparations may include biomarkers, such as disease biomarkers (diagnostic markers) for various disease (early stage and late stage cancers, neurological disorders (Parkinson disease, Alzheimer disease), diabetes, pancreatic diseases, renal failure, infectious diseases (HIV, tuberculosis, malaria, hepatitis)). The present methods and devices may be used to detect and monitor animals (human, live-stock, companion animal) for infectious diseases, such as tuberculosis and other diseases. The methods and devices require minimal sample material (10 μl), are rapid, economical, yield highly enriched small molecule (e.g., exosoines) preparations, and do not require electricity.



traducir


 

NON-HUMAN ANIMAL HAVING DYSTROPHY CAUSED BY PROTEIN AGGREGATION

NºPublicación: EP3424316A1 09/01/2019

Solicitante:
SMC GLOBAL ASSET INC [JP]

Resumen de: EP3424316A1

The present invention provides a model animal for establishing an effective therapy for a protein aggregation disease typified by Alzheimer's disease and the like. More specifically, the present invention provides the followings: (A) a non-human animal that exhibits a degenerative symptom attributed to protein aggregation, wherein the degenerative symptom attributed to protein aggregation is induced by misfolding of the protein and said degenerative symptom is promoted; and (B) a method for producing the non-human animal that exhibits the degenerative symptom attributed to the protein aggregation, comprising the following (1) and (2): (1) inducing misfolding of the protein to cause the degenerative symptom attributed to the protein aggregation in the non-human animal, and (2) giving a treatment to promote the degenerative symptom attributed to the protein aggregation in the non-human animal.



traducir


 

Blood test for screening out amyloid and Alzheimer's Disease presence

NºPublicación: AU2017281229A1 03/01/2019

Solicitante:
UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

Resumen de: AU2017281229A1

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFRl), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.



traducir


 

BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS

NºPublicación: US2019002544A1 03/01/2019

Solicitante:
ICB INT INC [US]

Resumen de: US2019002544A1

Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.



traducir


 

METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)

NºPublicación: US2019002826A1 03/01/2019

Solicitante:
NEW YORK STEM CELL FOUND INC [US]
ICAHN SCHOOL MED MOUNT SINAI [US]

Resumen de: US2019002826A1

The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.



traducir


 

DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET

NºPublicación: EP3420363A1 02/01/2019

Solicitante:
THE WEST VIRGINIA UNIV BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIV [US]

Resumen de: WO2017147114A1

Methods of detecting the signature of Alzheimer's disease before the clinical onset of the disease are disclosed, such as methods of diagnosing Mild Cognitive Impairment (MCI), monitoring the progress of MCI, and predicting the time to clinical onset of AD dementia. The methods use a Biomarker Severity Score, which corresponds to output signals of one or more biomarkers chosen from AD Index, Morphometric Imaging, and PKC Epsilon Biomarkers. Also disclosed are methods of screening for a compound useful for treating MCI or for preventing the clinical onset of AD dementia, as well as methods of evaluating or monitoring the therapeutic benefit of an agent for treating MCI or preventing the clinical onset of AD dementia.



traducir


 

NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS

NºPublicación: EP3422008A1 02/01/2019

Solicitante:
MCBI INC [JP]

Resumen de: EP3422008A1

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by Sequence Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by Sequence Nos. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.



traducir


 

NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS

NºPublicación: EP3422010A1 02/01/2019

Solicitante:
MCBI INC [JP]

Resumen de: EP3422010A1

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by Sequence Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by Sequence Nos. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.



traducir


 

NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS

NºPublicación: EP3422009A1 02/01/2019

Solicitante:
MCBI INC [JP]

Resumen de: EP3422009A1

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by Sequence Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by Sequence Nos. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.



traducir


 

PROCESS FOR IDENTIFYING AMYLOID PRECURSOR PROTEIN IN PROTEIN COMPLEXES OF HIGH MOLECULAR WEIGHT

NºPublicación: RO132970A2 28/12/2018

Solicitante:
INSTITUTUL NAT DE CERCETARE DEZVOLTARE IN DOMENIUL PATOLOGIEI SI STIINTELOR BIOMEDICALE VICTOR BABES [RO]

Resumen de: RO132970A2

The invention relates to a process for identifying native amyloid precursor protein in protein complexes of high molecular weight, isolated from cellular membranes, meant to be applied in Alzheimer's disease pathology. According to the invention, the process consists in separating the cell membranes from the other cell components, extracting the protein complexes with 0.5...1% detergent Triton-X 100 in 50...75 mM of imidazole buffer, followed by the separation of protein complexes by electrophoresis in polyacrylamide as gel, for 2...4 h, at constant amperage of 10mA/gel on ice, in electrophoresis buffer with a pH 8...10 and the complex transfer on transfer membrane, for 20...22 h, at constant amperage of 100 mA, on ice, followed by protein identification with specific antibodies.



traducir


 

TDP-43 IN DEGENERATIVE DISEASE

NºPublicación: US2018372756A1 27/12/2018

Solicitante:
UNIV JOHNS HOPKINS [US]

Resumen de: US2018372756A1

Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).



traducir


 

SYSTEM OF PREDICTING DEMENTIA AND OPERATING METHOD THEREOF

NºPublicación: US2018368699A1 27/12/2018

Solicitante:
GI SIGNAL LTD [KR]

Resumen de: US2018368699A1

A dementia prediction system and an operating method thereof are disclosed. The dementia prediction system includes a bio signal collection module configured to detect brainwave information and visual information of a subject and a brain aging determination module configured to calculate directional data of a bio signal of the subject from the brainwave information and the visual information and classify the directional data into a dementia group and a normal group using training data of a preset dementia group and a preset normal group.



traducir


 

SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF

NºPublicación: US2018371035A1 27/12/2018

Solicitante:
MASSACHUSETTS GEN HOSPITAL [US]

Resumen de: US2018371035A1

The disclosure provides novel forms of tau species and applications thereof, as well as methods of diagnosing and/or treating tau-associated neurodegeneration.



traducir


 

Human Anti-Alpha-Synuclein Antibodies

NºPublicación: US2018371065A1 27/12/2018

Solicitante:
BIOGEN INT NEUROSCIENCE GMBH [CH]
UNIV OF ZUERICH [CH]

Resumen de: US2018371065A1

Provided are novel human α-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.



traducir


 

METHOD FOR IDENTIFYING INHIBITORS OF PRIMARY NUCLEATION OF AMYLOID-BETA AGGREGATION

Nº publicación: CN109073656A 21/12/2018

Solicitante:
\u4E8E\u5229\u5947\u7814\u7A76\u4E2D\u5FC3\u6709\u9650\u516C\u53F8

Resumen de: WO2017186203A1

The invention relates to a method for identifying inhibitors of the primary nucleation of amyloid-beta aggregation, comprising the following steps: a) A-beta species is provided in a buffer; b) the amyloid-beta aggregation is determined. The method is characterised in that c) two A-beta monomer units with a linker arranged between the A-beta monomers is selected as the A-beta species. Also disclosed are a linker used for that purpose, a kit and the uses thereof.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver